This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid painkiller that could change the way doctors treat acute pain. The drug, developed by Vertex Pharmaceuticals,

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with acute pain. The FDA has approved the non-opioid, highly selective NaV1.8 pain signal inhibitor for administration twice daily.